新辅助化疗在进展期食管癌中的疗效分析

目的 :探讨新辅助化疗在进展期食管癌治疗中的意义。方法:回顾性研究272例进展期食管癌患者，其中112例行新辅助化疗+手术治疗，160例行单纯手术治疗，比较围手术期并发症发生率、手术切除率及术后生存期。 结果 :新辅助化疗组术后并发症发生率为34.8%（39/112），单纯手术组术为29.4%（47/160），P=0.50；两组5年生存率分别为:35.7%和29.4%，P < 0.05。化疗效果PR组和SD/PD组5年生存率分别为38.5%和30.1%，P < 0.01。 结论 :新辅助化疗未增加食管癌患者围手术期并发症的发生率，是安全可行的；新辅助化疗能提高进展期食管癌患者的生存率；化疗有效组患者预后好于化疗无效组。 

Effect of neoadjuvant chemotherapy on local advanced esophageal cancer

To discuss the significance of neoadjuvant chemotherapy followed by surgery in the treatment of local advanced esophageal cancer. Methods : A total of 272 cases of local advanced esophageal cancer were studied in retrospect. Out of the 272 cases, 112 were treated with neoadjuvant chemotherapy followed by surgery (CT-S), whereas the remaining 160 cases underwent surgical treatment (S) only. Complications and survival state after surgery were compared. Results : The rate of complications after surgery was as follows: CT-S: 34.8% (39/112); S: 29.4% (47/160), P=0.50. The five-year survival rate was 35.7% and 29.4%, respectively, P < 0.05. The CT-S patients were divided into partial remission (PR) and stable disease (SD)/progressive disease (PD) groups according to the effect of the chemotherapy. The five-year survival rate was 38.5% and 30.1%, respectively, P < 0.01. Conclusion : Neoadjuvant chemotherapy is available for local advanced esophageal cancer. Postoperative complications are not increased by chemotherapy, and the survival rate for local advanced esophageal cancer is improved by neoadjuvant chemotherapy. PR has better prognosis compared with SD/PD.